Interstitial lung diseases of unknown cause: disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts)
RG Crystal,PB Bitterman, SIRennard… - … England Journal of …, 1984 - Mass Medical Soc
THE interstitial lung diseases are a heterogeneous group of disorders of the lower respiratory
tract characterized by derangements of the alveolar walls and loss of functional alveolar …
tract characterized by derangements of the alveolar walls and loss of functional alveolar …
An official American Thoracic Society/European Respiratory Society statement: research questions in chronic obstructive pulmonary disease
…, W MacNee, BJ Make, SIRennard… - American journal of …, 2015 - atsjournals.org
Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity,
mortality, and resource use worldwide. The goal of this Official American Thoracic Society (…
mortality, and resource use worldwide. The goal of this Official American Thoracic Society (…
Pathogenesis of COPD
JR Spurzem, SIRennard- Seminars in respiratory and critical …, 2005 - thieme-connect.com
Chronic obstructive pulmonary disease (COPD) is characterized and defined by limitation of
expiratory airflow. This can result from several types of anatomical lesions, including loss of …
expiratory airflow. This can result from several types of anatomical lesions, including loss of …
Laminin-A糖蛋白from basement membranes.
R Timpl, H Rohde,PG Robey, SIRennard… - Journal of Biological …, 1979 - ASBMB
We have isolated a large noncollagenous glycoprotein, laminin, from a mouse tumor that
produces basement membrane. The protein consists of at least two polypeptide chains (Mr = …
produces basement membrane. The protein consists of at least two polypeptide chains (Mr = …
[HTML][HTML]A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
…, SJ Leischow, MA Nides, SIRennard… - … England Journal of …, 1999 - Mass Medical Soc
Background and Methods Use of nicotine-replacement therapies and the antidepressant
bupropion helps people stop smoking. We conducted a double-blind, placebo-controlled …
bupropion helps people stop smoking. We conducted a double-blind, placebo-controlled …
Chronic obstructive pulmonary disease phenotypes: the future of COPD
…, BJ Make,KF Rabe, SIRennard… - American journal of …, 2010 - atsjournals.org
Significant heterogeneity of clinical presentation and disease progression exists within
chronic obstructive pulmonary disease (COPD). Although FEV 1 inadequately describes this …
chronic obstructive pulmonary disease (COPD). Although FEV 1 inadequately describes this …
Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial
D Gonzales, SIRennard, M Nides, C Oncken… - Jama, 2006 - jamanetwork.com
ContextThe α4β2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing
effects of nicotine and maintaining smoking behavior. Varenicline, a novel α4β2 nAChR partial …
effects of nicotine and maintaining smoking behavior. Varenicline, a novel α4β2 nAChR partial …
[HTML][HTML]Changes in forced expiratory volume in 1 second over time in COPD
…,R Tal-Singer, E Wouters, SIRennard- … England Journal of …, 2011 - Mass Medical Soc
Background A key feature of chronic obstructive pulmonary disease (COPD) is an accelerated
rate of decline in forced expiratory volume in 1 second (FEV 1 ), but data on the variability …
rate of decline in forced expiratory volume in 1 second (FEV 1 ), but data on the variability …
[HTML][HTML]Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype
A Agustí, LD Edwards, SIRennard, W MacNee… - PloS one, 2012 - journals.plos.org
Background Because chronic obstructive pulmonary disease (COPD) is a heterogeneous
condition, the identification of specific clinical phenotypes is key to developing more effective …
condition, the identification of specific clinical phenotypes is key to developing more effective …
[HTML][HTML]A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci
…, W Anderson, ICGN Investigators, SIRennard… - PLoS …, 2009 - journals.plos.org
There is considerable variability in the susceptibility of smokers to develop chronic obstructive
pulmonary disease (COPD). The only known genetic risk factor is severe deficiency of α1-…
pulmonary disease (COPD). The only known genetic risk factor is severe deficiency of α1-…